These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11770280)

  • 21. Medications for postmenopausal osteoporosis prevention.
    Harv Womens Health Watch; 2002 Dec; 10(4):6-7. PubMed ID: 12499127
    [No Abstract]   [Full Text] [Related]  

  • 22. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
    Papapoulos SE
    Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931
    [No Abstract]   [Full Text] [Related]  

  • 23. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
    Curković B
    Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis management in the new millennium.
    Wei GS; Jackson JL; Hatzigeorgiou C; Tofferi JK
    Prim Care; 2003 Dec; 30(4):711-41, vi-vii. PubMed ID: 15024893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of bisphosphonates in the treatment of osteoporosis.
    Delmas PD
    Curr Opin Rheumatol; 2005 Jul; 17(4):462-6. PubMed ID: 15956844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of glucocorticoid-induced osteoporosis.
    Saag KG
    South Med J; 2004 Jun; 97(6):555-8. PubMed ID: 15255421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
    Orcel P
    Joint Bone Spine; 2005 Dec; 72(6):461-5. PubMed ID: 16326129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
    Compston JE
    Bone; 2000 Dec; 27(6):765-8. PubMed ID: 11113386
    [No Abstract]   [Full Text] [Related]  

  • 31. A review of combination regimens for osteoporosis--prevention and treatment.
    Miller E; Kalin MF
    Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for the prevention and treatment of osteoporosis during early postmenopause.
    Delaney MF
    Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S12-23. PubMed ID: 16448872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates: new indications and methods of administration.
    Reid IR
    Curr Opin Rheumatol; 2003 Jul; 15(4):458-63. PubMed ID: 12819475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on bisphosphonates.
    Cohen SB
    Curr Rheumatol Rep; 2004 Feb; 6(1):59-65. PubMed ID: 14713403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Osteoporosis therapy. A comparison of bisphosphonates].
    MMW Fortschr Med; 2002 Jul; 144(27-28):60. PubMed ID: 12198889
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based medicine: putting theory into practice.
    Irani M
    Hosp Med; 2001 Mar; 62(3):164-8. PubMed ID: 11291467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.